FineHeart
FineHeart is a French clinical-stage medical device company developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator that synchronizes with the native heartbeat via wireless power transfer to treat advanced heart failure patients in hospitals and cardiac surgery centers.
- Company typePrivate
- Founded2010
- HeadquartersBordeaux, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What FineHeart does
FineHeart is a French clinical-stage medical device company founded in 2010 and headquartered in Pessac (Bordeaux), developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator designed to treat advanced heart failure. The device is a catheter-deliverable intra-cardiac pump that synchronizes with the patient's native heartbeat to augment rather than replace natural ejection, powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and their associated infection risk. The technology is protected by 69+ patents globally including US Patent 11,097,093 covering device algorithms and granted Chinese patents, with potential applications spanning both temporary and permanent mechanical circulatory support.
The company's business model centers on Class III implantable hardware sales to hospitals and cardiac surgery centers through direct enterprise sales and hospital procurement processes following regulatory approval (CE marking in EU, FDA approval in US). As of late 2025, FineHeart had secured First-In-Human clinical trial authorizations from ANSM (France) and JAZMP (Slovenia) and announced successful first human implantations, but has not yet commercialized the product and generates no revenue. The company has cumulatively raised approximately €83 million through a Series C first closing (€35M, January 2026, co-led by Groupe Pasteur Mutualité and the EIC/EIB Fund) combined with €48M in non-dilutive IPCEI Tech4Cure grants, alongside prior Series B funding of €21M (2021), a €2.5M EIC Accelerator grant (2022), €7.8M France 2030 i-demo funding, and €750K ERDF support.
FineHeart has been designated lead partner of the IPCEI Tech4Cure consortium, a multi-country European initiative jointly notified by France, Hungary, Italy, Latvia, Slovakia, and Slovenia to structure the European Active Implantable Medical Devices sector. The company operates a 900 m² production facility in Pessac including a 100 m² ISO 7 cleanroom, is pursuing ISO 13485:2016 certification and EU MDR compliance, and is staffed by 11-50 employees including senior executives with prior tenures at Medtronic, GE Healthcare, Zimmer Biomet, and Pixium Vision.
FineHeart firmographics
Firmographics- Name
- FineHeart
- Legal name
- FineHeart S.A.
- Website
- https://fineheart.fr
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FineHeart is a French clinical-stage medical device company developing the ICOMS FLOWMAKER, a fully implantable intraventricular cardiac output accelerator that synchronizes with the native heartbeat via wireless power transfer to treat advanced heart failure patients in hospitals and cardiac surgery centers.
- Ownership category
- akta.pro rank
FineHeart industry classification
Industry- Product category
- Ventricular Assist Devices (Cardiac Assist Devices)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
Keywords
Where FineHeart is headquartered
LocationHeadquarters
- HQ city
- Bordeaux
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
FineHeart business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: FineHeart will generate revenue through the sale of the FlowMaker implantable cardiac device to hospitals and cardiac surgery centers. As a Class III implantable medical device, pricing will be determined through hospital procurement and reimbursement processes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | No public pricing tiers available |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
FineHeart product offering
Product offeringCore offering
FineHeart develops and manufactures the ICOMS FLOWMAKER®, a fully implantable intraventricular cardiac output accelerator that synchronizes to the patient's native heartbeat to restore natural cardiac pumping capacity. The device is powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and reducing infection risk. It is offered alongside a catheter-based delivery system for minimally invasive implantation, targeting advanced heart failure patients in hospital and cardiac surgery center settings.
Product overview
FineHeart offers a unified product ecosystem centered on the ICOMS FLOWMAKER®, the world's first fully implantable cardiac output accelerator for advanced heart failure. This system combines the main device with a wireless transcutaneous energy transfer (TET) system for power and a dedicated delivery system for minimally invasive implantation. The technology synchronizes with the native heartbeat to restore natural cardiac pumping capacity without the complications of traditional ventricular assist devices.
Differentiator
Problem solved
Functional benefit
Products and services
- ICOMS FLOWMAKER® The world's first fully implantable cardiac output accelerator designed to treat advanced heart failure. It is an intraventricular flow accelerator synchronized to the native heartbeat that restores the natural heart's pumping capacity, powered by a miniaturized internal battery recharged wirelessly via transcutaneous energy transfer. It is intended for hospitals and cardiac surgery centers treating advanced heart failure patients as a Class III implantable medical device.
- Wireless Transcutaneous Energy Transfer (TET) System Wireless power transfer system for powering the ICOMS FLOWMAKER® implantable heart pump, eliminating the need for percutaneous drivelines and reducing infection risk. The internal battery is rechargeable through the skin via a wireless external source.
- Delivery System Catheter-based delivery system for minimally invasive implantation of the ICOMS FLOWMAKER® device during beating-heart procedures, designed for use by cardiac surgeons and interventional cardiology teams.
Quantifiable outcome
- First-In-Human clinical trials authorized by ANSM (France) and JAZMP (Slovenia)
- +2 more outcomes
Companies that use FineHeart
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
FineHeart technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
FineHeart partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- IPCEI Tech4Cure ConsortiumflagshipFineHeart serves as lead partner of IPCEI Tech4Cure (Important Project of Common European Interest) jointly notified by France, Hungary, Italy, Latvia, Slovakia, and Slovenia. The €48 million grant supports structuring the European Active Implantable Medical Devices sector focusing on miniaturization, energy reduction, and long-term reliability.
Scale indicators9 records
Recent moves8 records
Expansion highlights5 records
FineHeart competitors and assessment
Company assessmentDirect peers
- Abbott: Abbott manufactures HeartMate 3, the market-leading left ventricular assist device (LVAD) for advanced heart failure. HeartMate 3 is the primary incumbent that FineHeart's FlowMaker aims to disrupt with its fully implantable, driveline-free architecture.
- Carmat: Carmat is a French clinical-stage company developing Aeson, a total artificial heart for patients with end-stage biventricular heart failure. Both companies are French clinical-stage cardiac implant developers addressing severe heart failure with novel mechanical support architectures.
- CorWave: CorWave is a French medtech company developing a novel implantable LVAD using a wave membrane pump technology. It is the closest French peer to FineHeart in developing next-generation mechanical circulatory support devices.
- Berlin Heart: Berlin Heart develops ventricular assist devices (VADs) for pediatric and adult patients, including the EXCOR and newer implantable systems. It directly competes in the mechanical circulatory support space targeting heart failure patients.
- ReliantHeart: ReliantHeart develops the HeartAssist5 and aVAD, a next-generation LVAD with remote monitoring capabilities. It competes in the same advanced heart failure mechanical support category as FineHeart.
- SynCardia Systems: SynCardia manufactures the SynCardia Total Artificial Heart, a permanent mechanical replacement for both ventricles in end-stage heart failure patients. It competes in the severe heart failure treatment space served by FineHeart.
- Evaheart: Evaheart develops the EVAHEART LVAD, a continuous-flow left ventricular assist system for advanced heart failure patients. It is a direct competitor in the implantable mechanical circulatory support device category.
Broad incumbents
- Medtronic: Medtronic historically competed in the LVAD market with the HVAD system (now discontinued) and remains a major cardiac device incumbent. Medtronic's scale, clinical infrastructure, and existing heart failure portfolio position it as a potential acquirer or competitor to FineHeart.
Emerging players
- Calon Cardio: Calon Cardio is a UK-based medtech developing the MiniVAD, a next-generation miniaturized ventricular assist device. It competes with FineHeart in developing smaller, less invasive mechanical circulatory support technologies.
- CH Biomedical: CH Biomedical is an emerging Chinese-American LVAD developer focused on next-generation ventricular assist technologies. It is a relevant emerging competitor in the implantable mechanical heart support category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
FineHeart social profiles
Digital presenceFineHeart compliance and trust
Trust signalCompliance4 records
FineHeart financial estimates
Financial estimateRevenue estimate
Valuation estimate
FineHeart leadership team
Management profileNumber of profiles
Profiles12 records
FineHeart funding detail
Funding detailFunding overview
Funding rounds6 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FineHeart M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FineHeart
What does FineHeart do?
FineHeart develops and manufactures the ICOMS FLOWMAKER®, a fully implantable intraventricular cardiac output accelerator that synchronizes to the patient's native heartbeat to restore natural cardiac pumping capacity. The device is powered by a miniaturized internal battery recharged through wireless transcutaneous energy transfer (TET), eliminating percutaneous drivelines and reducing infection risk. It is offered alongside a catheter-based delivery system for minimally invasive implantation, targeting advanced heart failure patients in hospital and cardiac surgery center settings.
Is FineHeart a public or private company?
FineHeart is a private company. It is classified as venture growth investor backed and is currently operating.
When was FineHeart founded?
FineHeart was founded in 2010. It employs 11 to 50 people.
Where is FineHeart based?
FineHeart is headquartered in Bordeaux, France, in the Europe region.
How does FineHeart make money?
One revenue line is on record: medical Device Sales.
Who are FineHeart's main competitors?
Direct peers on record are Abbott, Carmat, CorWave, Berlin Heart, ReliantHeart, SynCardia Systems and Evaheart. Medtronic is listed as a broad incumbent. Emerging players are Calon Cardio and CH Biomedical.
Does FineHeart have an API?
No public API is recorded for FineHeart.
What industry is FineHeart in?
FineHeart's product category is Ventricular Assist Devices (Cardiac Assist Devices). Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3845.